Johnson & Johnson picked up a plant in Vacaville, California, nearly 20 years ago with its $10.5 billion buyout of Alza, a deal that also gave it attention-deficit disorder drug Concerta and cancer drug Doxil. Janssen is now focused in other areas and has decided the plant is no longer needed.
Nearly 50 employees are slated to be let go next week, according to a California WARN notice (PDF), as J&J’s pharmaceutical unit Janssen begins a three-year phaseout, a spokesman said in an email. The company declined to say how many total employees work there.
J&J says the closure is part of an effort to rework its manufacturing network as its drug portfolio changes.
“As part of this transformation, we will scale down production at our Vacaville, California facility with the intent to fully exit the site by the end of 2022,” J&J spokesman Matthew Johnson said.
Janssen, like other drugmakers, is putting more effort into areas such as immunology that involve biologic drugs. In the fourth quarter, sales of its Stelara worldwide grew by 33.6% on the back of its launch in Crohn’s disease, while psoriasis drug Tremfya has nabbed a 6.6% share of an ultracompetitive U.S. market since its July 2017 debut.
By Eric Palmer
Source: Fierce Pharma
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.